ESCROW AGREEMENT FOR SECURITIES OFFERINGEscrow Agreement • July 8th, 2020 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Delaware
THIS ESCROW AGREEMENT, dated as of 6/17/20 (“Escrow Agreement”), is by and between SI Securities, LLC (“SI Securities”), 20/20 GeneSystems, Inc., a Delaware corporation (“Issuer”), and The Bryn Mawr Trust Company of Delaware (“BMTC DE”), a Delaware entity, as Escrow Agent hereunder (“Escrow Agent”). Capitalized terms used herein, but not otherwise defined, shall have the meaning set forth in that certain Issuer Agreement by and between Issuer and SI Securities executed prior hereto (the “Issuer Agreement”).
SUBSCRIPTION AGREEMENTSubscription Agreement • August 1st, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Delaware
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.
POSTING AGREEMENTPosting Agreement • December 31st, 2019 • 20/20 GeneSystems, Inc. • Services-testing laboratories • California
ContractQuotation Agreement • February 25th, 2021 • 20/20 GeneSystems, Inc. • Services-testing laboratories • California
THIS QUOTATION AGREEMENT, dated as of the date executed by StartEngine Primary, LLC, a Delaware limited liability company (“Primary”), with an office at 3900 W Alameda Ave, Suite 1200, Burbank, CA 91505, is by and between Primary and the Company, as identified below (the “Company”).
October 26, 2017Option Agreement to License and Commercialize Pan-Cancer Test Algorithm • June 22nd, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories
Pursuant to discussions between the Parties, the Option Agreement to License and Commercialize Pan-Cancer Test Algorithm (“Agreement”) between CGMH and 20/20 GeneSystems shall be amended as follows:
COLLABORATIVE RESEARCH AGREEMENTCollaborative Research Agreement • April 29th, 2024 • 20/20 GeneSystems, Inc. • Services-testing laboratories
This Collaborative Research Agreement (“Agreement”), effective as of Effective Date as defined in the License Agreement referenced in Recital C (the “Effective Date”) is made by and between The University of Texas M. D. Anderson Cancer Center, (“MD Anderson”), a member institution of The University of Texas System (“System”), with a place of business at 1515 Holcombe Blvd., Houston, Texas, 77030, and 20/20 GeneSystems Inc., a corporation with a place of business at 15810 Gaither Drive, Suite 235, Gaithersburg, MD 20877 (“Sponsor”). MD Anderson and Sponsor hereinafter may be referred to each as a “Party” and collectively as the “Parties.”
SI Securities, LLCOffering Agreement • June 22nd, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • New York
Sales Representative AgreementSales Representative Agreement • July 6th, 2020 • 20/20 GeneSystems, Inc. • Services-testing laboratories
This Sales Representative Agreement (“Agreement”) is made this 5th day of April, 2020 (“Effective Date”) between MEMS TECHNOLOGIES HOLDINGS COMPANY LIMITED. having a location at Room 909, 9/F., APEC Plaza, 49 Hoi Yuen Road, Kwun Tong, Kowloon, Hong Kong (“MEMS”) and 20/20 BioResponse, a business unit of 20/20 GeneSytems, Inc. having its headquarters at 9430 Key Wes Avenue, Rockville, Maryland, United States of America 20850 (“20/20”).
20/20 GENESYSTEMS, INC. SERIES C PREFERRED STOCK SUBSCRIPTION AGREEMENT NOTICE TO SUBSCRIBERSSeries C Preferred Stock Subscription Agreement • July 8th, 2020 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Delaware
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, SUBSCRIBERS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES.
PUBLIC HEALTH SERVICE SECOND AMENDMENT TO L-216-2000/0L-216-2000/0 • July 11th, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories
This is the second amendment (“Second Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) or the Food and Drug Administration (“FDA”), hereinafter singly or collectively referred to as agencies of the United States Public Health Service (“PHS”) within the Department of Health and Human Services (“HHS”), and 20/20 GeneSystems, Inc. having an effective date of November 9, 2000, and having NIH Reference Number L-216-2000/0, as amended by the first amendment to the agreement, having an effective date of April 14, 2005, and having NIH reference Number L-216-2000/1 (“First Amendment”) (hereinafter collectively referred to as the “Agreement”). This Second Amendment, having NIH Reference Number L-216-2000/2, is made between the PHS through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and 20/20 GeneSystems, Inc., having an office at 9430 Key West Ave. Rockville, MD 2085
STARTENGINE PRIMARY LLC ENGAGEMENT LETTEREngagement Letter • November 26th, 2019 • 20/20 GeneSystems, Inc. • Services-testing laboratories • California
LICENSE AMENDMENTLicense Agreement • July 11th, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories
WHEREAS, the National Institutes of Health (“NIH”) on behalf of the Public Health Service (“PHS”), Department of Health and Human Services (“DHHS”) and 20/20 GeneSystems, Inc. (“Licensee”) entered into a license agreement (PHS Ref. L-216-2000/0; “Agreement”) effective November 9, 2000, relating to U. S. Patent Application S/N 60/145,613, filed July 26, 1999, entitled “Methods for Production of Layered Expression Scans for Tissue and Cell Samples” (and PCT filed on July 26, 2000, PCT/US00/20354); and
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT--EXCLUSIVE COVER PAGEPatent License Agreement • July 11th, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • District of Columbia
US Patent Application Serial No. 60/145,613 entitled “Method for Production of Layered Expression Scans for Tissue and Cell Samples”, filed 07/26/99. PCT filed 07/26/2000 (PCT/US00/20354)
AMENDMENT TO ISSUER AGREEMENTIssuer Agreement • August 1st, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • New York
THIS AMENDMENT LETTER (the “Letter”) is entered into as of July 31, 2018 (the “Effective Date”) by and among 20/20 GeneSystems, Inc. (the “Company”) and SI Securities, LLC (“SI Securities”, and together with Company, the “Parties”).
CANCER EARLY DETECTION ALGORITHM DEVELOPMENT COLLABORATION AGREEMENTDevelopment Collaboration Agreement • June 22nd, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Maryland
THIS DEVELOPMENT COLLABORATION AGREEMENT (this “Agreement”) having an effective date of February 26, 2016 (“Effective Date”), is entered into by and between National Foundation for Cancer Research, Inc., 4600 East West Highway, Suite 525, Bethesda, Maryland 20814 (“NFCR”) and 20/20 GenesyStems, Inc., 9430 Key West Avenue, Rockville, MD 20850 (“20/20”).
Option Agreement to License and Commercialize Pan-Cancer Test Algorithm Not binding until signed by authorized representatives of both parties. This draft document does not require either party to enter into an agreement.Option Agreement • June 22nd, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories
THIS OPTION AGREEMENT (“Agreement”) is entered into by and between Chang Gung Memorial Hospital, Linkou (“CGMH”) of Taiwan, a foundation organized and existing under the laws of Taiwan, having an address at No. 5, Fuxing St., Guishan Dist., Taoyuan City 333, Taiwan (R.O.C.), (“CGMH”), and 20/20 GeneSystems, a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 9430 Key West Avenue, Suite 100, Rockville, MD, (“20/20”) as of the Effective Date.
Project Accelerator Program AWARD AND ROYALTY AGREEMENTAward and Royalty Agreement • July 11th, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Maryland
THIS AWARD AND ROYALTY AGREEMENT is made this 19th day of July 2002, by and between MdBio, Inc., a Maryland non-stock, not-for-profit corporation ("MdBio") and 20/20 GeneSystems, Inc., a Delaware corporation with its headquarters located at Rockville, Maryland ("20/20").
SI Securities, LLCPlacement Agent Agreement • July 8th, 2020 • 20/20 GeneSystems, Inc. • Services-testing laboratories • New York
CONVERTIBLE BONDS SUBSCRIPTION AGREEMENTConvertible Bonds Subscription Agreement • April 29th, 2024 • 20/20 GeneSystems, Inc. • Services-testing laboratories • New York
This Convertible Bonds Subscription Agreement, dated as of March 20, 2024 (this “Agreement”), is entered into by and between 20/20 GeneSystems, Inc., a Delaware corporation having its main office at 15810 Gaither Dr., Suite 235, Gaithersburg, Maryland, U.S.A. (the “Company”), and Cornerstone Investment Inc., a Korean corporation having its registered office at 21F S-Tower, 82 Saemunan-ro, Jongno-gu, Seoul, Korea (the “Investor”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 12th, 2019 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Delaware
EMPLOYMENT AGREEMENT (this “Employment Agreement”), dated May 6, 2019, between 20/20 GENESYSTEMS, INC., a Delaware corporation (the “Company”), and JONATHAN M. COHEN, an individual with his principal residence at 10405 Broadfield Court, Potomac, MD 20854 (the “Executive”).
Option AgreementOption Agreement • April 29th, 2024 • 20/20 GeneSystems, Inc. • Services-testing laboratories
This Option Agreement (“Agreement”) is made as of the date of the last authorized signature below (the “Effective Date”), by and between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas, whose address is 210 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas M. D. Anderson Cancer Center (“MD Anderson”), a member institution of System, and 20/20 GeneSystems Inc., having a principal place of business located at 15810 Gaither Drive, Suite 235, Gaithersburg MD 20877 (“Company”).
SUBSCRIPTION AGREEMENTSubscription Agreement • August 14th, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Delaware
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.
